JARDIANCE (Boehringer Ingelheim Pty Ltd)
Product name
JARDIANCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
empagliflozin
Registration type
EOI
Indication
Chronic kidney disease
JARDIANCE is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (CKD Stages 2 and 3A with urine ACR ≥30 mg/g, or CKD Stages 3B, 4 and 5 irrespective of urine ACR).